マーケットレポート詳細

CAR-T細胞療法：研究開発状況および世界市場

Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

出版元：BCC Research 　 出版元について
発行年：2021年12月
定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文353ページになります。
商品コード：BCC345

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

CAR-T細胞療法（キメラ抗原受容体-T細胞療法）の世界市場規模は2021年で15億ドル、2026年には76億ドルに拡大する見込みです。同市場の平均年成長率(CAGR)は39.1%増での推移と予測されます。
CAR-T細胞療法で現在FDAの承認が下りている製剤は5種類あります。Bristol Myers SquibbからAbecma（2021年3月上市）およびBreyanzi(2021年2月)、Kite PharmaからTecartus(2020年7月)とYescarta(2017年10月)、そしてNovartisからKymriah（2017年8月）、となっています。

当レポートでは、CAR-T細胞療法の市場/技術的背景、COVID-19による影響、現在の製造方法、最新の技術的進歩および将来の方向性、地域分析、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆CAR-T細胞療法：序論

・CAR-T細胞療法開発の簡略な歴史
・抗原
・分化のクラスター
・リンパ球
・養子細胞移植(ACT)技術

◆COVID-19による影響

◆市場ダイナミクス

・市場ダイナミクス

◆現在の製造方法、最新の技術的進歩および将来の方向性

・CAR-T細胞の産生
・CAR-T細胞製造の課題の克服
・産生プロセスの最新の進歩

◆CAR-T細胞および関連技術に関する臨床試験

・世界的に実施されている臨床試験
・米国におけるCAR-T細胞、臨床試験の分布
・中国におけるCAR-T細胞、臨床試験の分布

◆がん人口統計：グローバルサマリー

・がん：病気
・がんの種類/部位別の疫学
・地域別のがん疫学
・世界的ながん負担と世界的ながんの危険因子

◆CAR-T細胞市場分析

CAR-T細胞市場

◆地域分析

・北米
・欧州
・アジア太平洋
・その他地域
※市場予測データ-2026年掲載
※地域別に製品別のデータ掲載

◆規制および立法要件

・北米
・欧州
・アジア太平洋
・中南米
・中東アフリカ
・細胞ベースの治療法の製造と試験に関する公表されたガイドライン

◆特許レビュー/新展開

・企業別の知的財産及び特許情報

◆競合状況

・CAR-T細胞市場シェア分析
・製品発売
・戦略的イニシアチブ
・合併と買収

◆主要企業プロフィール

・ABBVIE INC.
・AMGEN
・ASTRAZENECA
・AVACTA LIFE SCIENCES LTD.
・BELLICUM PHAMACEUTICALS
・BLUEBIRD BIO
・BRISTOL MYERS SQUIBB
・CELLECTIS
・CELYAD SA
・EDITAS MEDICINE INC.
・EUREKA THERAPEUTICS INC.
・FORMULA PHARMACEUTICALS INC.
・GILEAD SCIENCES
・F. HOFFMAN-LA ROCHE AG
・ICELL GENE THERAPEUTICS
・MUSTANG BIO INC.
・NOILE-IMMUNE BIOTECH
・NOVARTIS AG
・PROTHERAGEN INC.
・PURETECH HEALTH
・SERVIER LABORATORIES
・武田薬品工業株式会社
・TRANSGENE SA

(全353頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

Scope of This Report
What's New in this Update?
Methodology and Information Sources

Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

CAR T-Cell Design and Evolution
FDA Product Approvals
Market Analysis
Clinical Applications of CAR T-Cell Therapy

Barriers to Research and Product Development
Clinical Trials

Chapter 3 Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy

Introduction
A Brief History of CAR T-Cell Therapy Development
Antigens

Cluster of Differentiation
Lymphocytes

Adoptive Cell Transfer (ACT) Technologies

Chapter 4 Impact of COVID-19 on the Market

Overview

Chapter 5 Market Dynamics

Market Dynamics

Chapter 6 Current Production Methods, Latest Technological Advances and Future Direction

Production of CAR T Cells

Overcoming CAR T-Cell Manufacturing Challenges
Latest Advances in Production Processes

Chapter 7 Clinical Trials on CAR T Cells and Related Technologies

Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Trials in the U.S.
Distribution of CAR T-Cell Clinical Trials in China

Chapter 8 Cancer Demographics: A Global Summary

Cancer: The Disease
Epidemiology by Cancer Type/Site

Cancer Epidemiology by Region

Global Cancer Burden and Worldwide Cancer Risk Factors

Chapter 9 Global CAR T-Cell Market Analysis

Introduction
Global CAR T-Cell Market

Chapter 10 Regional Analysis

North America
Europe
Asia-Pacific
Rest of the World

Chapter 11 Regulatory and Legislative Requirements

North America

Europe

Asia-Pacific

Central and South America

Middle East and Africa

Published Guidelines on Production and Testing of Cell-Based Therapies

Chapter 12 Patent Review/New Developments

Introduction

Company Specific Intellectual Property and Patent Information

Chapter 13 Global Competitive Market Landscape

Global CAR T-Cell Market Share Analysis

Product Launches
Strategic Initiatives
Mergers and Acquisitions

Chapter 14 Company Profiles

ABBVIE INC.
AMGEN
ASTRAZENECA
AVACTA LIFE SCIENCES LTD.
BELLICUM PHAMACEUTICALS
BLUEBIRD BIO
BRISTOL MYERS SQUIBB
CELLECTIS
CELYAD SA
EDITAS MEDICINE INC.
EUREKA THERAPEUTICS INC.
FORMULA PHARMACEUTICALS INC.
GILEAD SCIENCES
F. HOFFMAN-LA ROCHE AG
ICELL GENE THERAPEUTICS
MUSTANG BIO INC.
NOILE-IMMUNE BIOTECH
NOVARTIS AG
PROTHERAGEN INC.
PURETECH HEALTH
SERVIER LABORATORIES
TAKEDA PHARMACEUTICALS
TRANSGENE SA

Chapter 15 Appendix A
Company Contact Details
Chapter 16 Appendix B
Government Regulatory Agencies and Professional Organizations
Chapter 17 Appendix C
Commonly Used Acronyms Associated with CAR T-Cell Therapy
Chapter 18 Appendix D
Recent Patent Applications Filed Related to CAR T-Cell Therapy
Chapter 19 Appendix E
CAR T-Cell and CD19 Clinical Trials in China

List of Tables

Summary Table A : Global CAR T-Cell Market, by Region, Through 2026
Summary Table B : Global CAR T-Cell Market, by Product, Through 2026
Table 1 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 2 : List of Relevant Human Clusters of Differentiation
Table 3 : Classification of Natural Killer T Cells
Table 4 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 5 : Tumor-Associated Antigens of CAR T-Cell Target
Table 6 : Reported COVID-19 Confirmed Cases and Deaths, by Country, October 22, 2021
Table 7 : Supplementary Components in CAR T-Cell Manufacture
Table 8 : Technologies Used in the Selection, Isolation and Enrichment of Cells During the Manufacture of CAR T Cells
Table 9 : Technologies Used in the Activation and Simulation of Cells During the Manufacture of CAR T Cells
Table 10 : Technologies Used in the Gene Transfer and Delivery of Cells During the Manufacture of CAR T Cells
Table 11 : Gene Transfer and Gene Delivery Technologies Developed by Poseida Therapeutics Inc.
Table 12 : Technologies Used in the Expansion and Culture of Cells During the Manufacture of CAR T Cells
Table 13 : Technologies Used in the Formulation of Cells During the Manufacture of CAR T Cells
Table 14 : Technologies Used in the Cryopreservation of Cells During the Manufacture of CAR T Cells
Table 15 : Technologies Used in the Thawing of Cells During the Manufacture of CAR T Cells
Table 16 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 17 : Global CAR T-Cell Clinical Trial Activity, by Study Location/Region, as of Oct. 2021
Table 18 : Clinical Trials on CD19 Directed CAR T-Cells in the U.S.
Table 19 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 20 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 21 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 22 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 23 : Global Cancer Incidence, by Cancer Type/Site, 2020
Table 24 : Global Cancer Mortality, by Cancer Type/Site, 2020
Table 25 : Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021
Table 26 : Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021
Table 27 : Global CAR T-Cell Market, by Product, 2026
Table 28 : Global CAR T-Cell Market, by Region, Through 2026
Table 29 : Global CAR T-Cell Market Share, by Region, 2021
Table 30 : North American CAR T-Cell Market, Through 2026
Table 31 : North American CAR T-Cell Market, by Product, Through 2026
Table 32 : European CAR T-Cell Market, Through 2023
Table 33 : European CAR T-Cell Market, by Product, Through 2026
Table 34 : Asia-Pacific CAR T-Cell Market, Through 2023
Table 35 : Asia-Pacific CAR T-Cell Market, by Product, Through 2026
Table 36 : Rest of the World CAR T-Cell Market, Through 2020-2026
Table 37 : Rest of the World CAR T-Cell Market, by Product, Through 2026
Table 38 : Overview of Healthcare System in India
Table 39 : Recent CAR T-Cell Therapy Patents and Patent Applications, 2020-2021
Table 40 : Recent Bluebird Bio Patents and Patent Applications, 2010-Apr. 2021
Table 41 : Recent Celgene Patents and Patent Applications, 2018-2021
Table 42 : Recent Cellectis Patents and Patent Applications, 2018-2021
Table 43 : Editas Medicine Patent Applications, 2010-2021
Table 44 : Eureka Therapeutics Patent Applications, 2015-2021
Table 45 : Kite Pharma’s (Gilead Sciences Subsidiary) Core Anticancer Technology: Yeda Research and Development Co., Ltd. Patents and Patent Applications, 1993-Apr. 2021
Table 46 : iCell Gene Therapeutics Patent Applications
Table 47 : Juno Therapeutics Inc. and Memorial Sloan Kettering Patents and Patent Applications
Table 48 : Mustang Bio and City of Hope National Medical Center Patents and Patent Applications
Table 49 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications
Table 50 : Novartis AG and University of Pennsylvania Patents and Patent Applications, 2013-2021
Table 51 : Global CAR T-Cell Market Share, by Company, 2021
Table 52 : Global CAR T-Cell Therapy Market, by Company Revenue, 2018-2021
Table 53 : New Product Launches in the CAR T-Cell Therapy Market
Table 54 : New Strategic Initiatives in CAR T-Cell Therapy Market
Table 55 : Mergers and Acquisitions in the CAR T-Cell Therapy Market, 2018-2021
Table 56 : Regulatory Approvals in the CAR T-Cell Therapy Market, 2018-2021
Table 57 : AbbVie Inc.: Marketed Products
Table 58 : AbbVie Inc.: Net Revenue, 2017-2020
Table 59 : AbbVie Inc.: Key Developments
Table 60 : Amgen: Financials, 2014-2020
Table 61 : Amgen: Financials, by Product, 2014-2020
Table 62 : Avacta Group plc: Financials, 2015-2017
Table 63 : Bellicum Pharmaceuticals Inc.: Financials, 2019 and 2020
Table 64 : Bellicum Pharmaceuticals Inc.: Key Switch Technologies
Table 65 : Bluebird Bio: Financials, 2018-2020
Table 66 : Bluebird Bio: Key Developments
Table 67 : Bristol-Myers Squibb: Net Revenue, 2017-2020
Table 68 : Bristol-Myers Squibb: Key Cancer Biologics Product Portfolio
Table 69 : Bristol-Myers Squibb: Key Developments
Table 70 : Juno Therapeutics: Product Pipeline
Table 71 : Editas Medicine Inc.: Financials, 2015-2020
Table 72 : Editas Medicine Inc.: Key Developments
Table 73 : Gilead Sciences: Financials, 2014-2020
Table 74 : Gilead Sciences: Key CAR T-Cell Therapies
Table 75 : Gilead Sciences: Individual Product Sales, 2018-2020
Table 76 : Gilead Sciences: Product Pipeline
Table 77 : F. Hoffman-La Roche: Financials, 2019 and 2020
Table 78 : F. Hoffman-La Roche: Pharmaceutical Division Financials, 2019 and 2020
Table 79 : F. Hoffman-La Roche: Total Revenue, by Geography, 2020
Table 80 : iCell Gene Therapeutics: Product Development Pipeline
Table 81 : Mustang Bio Inc.: Research and Development Pipeline
Table 82 : Novartis AG: Revenues, by Segment, 2019 and 2020
Table 83 : Protheragen: Enabling Technologies
Table 84 : PureTech Health: Immune System Pipeline
Table 85 : Takeda Pharmaceuticals: Financials, 2014-2016
Table 86 : Company Contact Details
Table 87 : Government Regulatory Agencies and Professional Organizations Associated with CAR T-Cell Therapy
Table 88 : Commonly Used Acronyms Associated with CAR T-Cell Therapy
Table 89 : Recent Patent Applications Filed Related to CAR T-Cell Therapy
Table 90 : CAR T-Cell and CD19 Clinical Trials in China

List of Figures

Summary Figure A : Global CAR T-Cell Market Share, by Region, 2021
Summary Figure B : Global CAR T-Cell Market, by Product, 2018-2026
Summary Figure C : Global CAR T-Cell Clinical Trials, by Phase, as of October 2021
Figure 1 : Historical Development of CAR T-Cell Therapy
Figure 2 : Cytotoxic T-Cell Activation and Action
Figure 3 : Overview of Signal Transduction Pathways Involved in Apoptosis
Figure 4 : Model for Th Differentiation from Naïve CD4+ T Cells
Figure 5 : Diagram of Regulatory T Cell, Effector T Cells and Dendritic Cells Showing Putative Mechanisms of Suppression by Regulatory T Cells
Figure 6 : Interactions and Cross Talk Between Different Subsets of NKT Cells and Other Immune Cells in TME
Figure 7 : Schematic of Adoptive Cell Transfer Therapies
Figure 8 : Structure and Function of the TCR
Figure 9 : General Structure of a Chimeric Antigen Receptor
Figure 10 : CAR T-Cell Design
Figure 11 : CAR T-Cell Manufacture and Product Testing Process
Figure 12 : Sleeping Beauty (SB) Transposon System Mechanism Schematic
Figure 13 : PiggyBac (PB) Transposon System “Cut and Paste” Mechanism Schematic
Figure 14 : CRISPR/Cas9 System Mechanism Schematic
Figure 15 : Global CAR T-Cell Clinical Trial Activity, by Phase, as of Oct. 2021
Figure 16 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2005-Oct. 2021
Figure 17 : Distribution Map of CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 18 : Distribution Map of CAR T-Cell Clinical Trial Activity in Europe, by Study Location/Country, as of Oct. 2021
Figure 19 : Distribution Map of Phase I CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 20 : Distribution Map of Phase II CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 21 : Distribution Map of Phase III CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 22 : Distribution Map of CAR T-Cell Clinical Trial Activity in the U.S., by Study Location, as of Oct. 2021
Figure 23 : Distribution of CAR T-Cell Clinical Trials in China, South Korea and Taiwan, by Study Location/Region, as of Oct. 2021
Figure 24 : CAR T-Cell Clinical Trials in China, by Study Start Date and Phase, 2006-Oct. 2021
Figure 25 : Global Cancer Incidence, by Sex and Cancer Type/Site, 2020
Figure 26 : Global Cancer Incidence, by Region, 2020
Figure 27 : Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030
Figure 28 : Global Cancer Prevalence by Cancer Type/Site and Sex, 2020
Figure 29 : Global CAR T-Cell Market, by Product, 2018-2026
Figure 30 : Global Market for Yescarta Cell Therapy, by Region, 2017-2021
Figure 31 : Global Market Shares of Yescarta Cell Therapy, by Region, 2020
Figure 32 : Global Market for Tecartus, by Region, 2020-2021
Figure 33 : Global Market Shares of Tecartus, by Region, 2020
Figure 34 : Global Market for Kymriah, by Region, 2017-2021
Figure 35 : Global Market Shares of Kymriah, by Region, 2020
Figure 36 : Global CAR T-Cell Market Share, by Region, 2021
Figure 37 : Drug Discovery and Development Timeline
Figure 38 : Mutual Recognition Procedure
Figure 39 : Decentralized Procedure
Figure 40 : Japanese Drug Funding/Reimbursement Approval Procedure
Figure 41 : The Chinese Healthcare System
Figure 42 : Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days* for Approval**
Figure 43 : Current Structure of the Health Care Sector in Saudi Arabia
Figure 44 : Global CAR T-Cell Therapy Market Share, by Company, 2021
Figure 45 : AbbVie Inc.: Revenue Share, by Country, 2020
Figure 46 : Bellicum Pharmaceuticals Inc.: Product Pipeline
Figure 47 : Bristol-Myers Squibb: Revenue Share, by Segment, 2020
Figure 48 : Bristol-Myers Squibb: Revenue Share, by Region, 2020
Figure 49 : Cellectis: Allogeneic CAR-T Pipeline
Figure 50 : Eureka Therapeutics Inc.: Product Pipeline
Figure 51 : Formula Pharmaceuticals Inc.: Product Pipeline
Figure 52 : Kite Pharma Inc. (a Subsidiary of Gilead Sciences Inc.): CAR and TCR Pipeline
Figure 53 : Noile-Immune Biotech: CAR Pipeline
Figure 54 : Novartis AG: Sales Prediction for Kymriah
Figure 55 : Protheragen: Product Pipeline


△ 一番上に戻る